These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 21619383)

  • 41. Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously.
    Rónaszéki A; Alings M; Egstrup K; Gaciong Z; Hranai M; Király C; Sereg M; Figatowski W; Bondarov P; Johansson S; Frison L; Edvardsson N; Berggren A
    Europace; 2011 Aug; 13(8):1148-56. PubMed ID: 21561900
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized invasive cardiac electrophysiology study of the combined ion channel blocker AZD1305 in patients after catheter ablation of atrial flutter.
    Toivonen L; Raatikainen P; Walfridsson H; Englund A; Hegbom F; Anfinsen OG; Gjesdal K; Pehrson S; Johansson S; Frison L; Berggren AR; Edvardsson N
    J Cardiovasc Pharmacol; 2010 Sep; 56(3):300-8. PubMed ID: 20588189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves.
    Sicouri S; Carlsson L; Antzelevitch C
    J Pharmacol Exp Ther; 2010 Jul; 334(1):255-9. PubMed ID: 20360353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog.
    Burashnikov A; Zygmunt AC; Di Diego JM; Linhardt G; Carlsson L; Antzelevitch C
    J Cardiovasc Pharmacol; 2010 Jul; 56(1):80-90. PubMed ID: 20386458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial.
    Egstrup K; Bergfeldt L; Duris T; Gullestad L; Kochmanski M; Kuśnierz B; Nielsen T; Sawicki S; Aunes-Jansson M; Edvardsson N; Frison L; Johansson S; Berggren A
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):199-208. PubMed ID: 21619383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 48.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 49.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.